William Ransom and Son to be bought by OBG Pharmaceuticals

William Ransom and Son is to be purchased by OBG Pharmaceuticals in a deal worth approximately 350,000 pounds.

The business unit, which represents the pharmaceuticals operation of the Ransom healthcare company, comes as part of a wider series of restructuring initiatives taking place at Ransom in recent months.

In March 2011, Ransom divided its operations into three subsidiary units, with the William Ransom and Son pharmaceuticals division complemented by separate consumer health and natural products units.

Sir Roger Jones, chairman of the organisation, said the sale of this business has been a long-held strategic goal that will ultimately benefit Ransom and its shareholders.

"The divestment is consistent with the company's strategy of creating a focused, higher margin, differentiated natural consumer healthcare business," he explained.

Ransom has been in operation since 1846 and is one of the oldest and most prominent natural healthcare firms in the UK.